Karger Kompass Onkologie最新文献_第6页

Nur wer testet, kann profitieren 只有测谎者才能受益

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000497261

N. Reinmuth

{"title":"Nur wer testet, kann profitieren","authors":"N. Reinmuth","doi":"10.1159/000497261","DOIUrl":"https://doi.org/10.1159/000497261","url":null,"abstract":"Objective: Latin American countries are heterogeneous in terms of lung cancer incidence and exposure to potential carcinogens. We evaluated the frequency and clinical characteristics of ALK rearrangements (ALKr) in Latin America. Methods: A total of 5,130 lung cancer patients from 10 Latin American countries were screened for inclusion. ALKr detection was performed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and real-time reverse transcriptase-polymerase chain reaction (RT-PCR) to assess method variability. Demographic and clinicopathologic characteristics were analyzed. Results: Among the 5,130 patients screened, 8.4% (n = 433) had nonevaluable FISH tests. Evaluable FISH analyses revealed positive ALKr in 6.8% (320/4,697) of the study population, which included patients from 9 countries. ALKr distribution for each country was: Mexico 7.6% (79/1,034), Colombia 4.1% (10/242), Argentina 6.0% (153/2,534), Costa Rica 9.5% (13/137), Panama 4.4% (5/114), Uruguay 5.4% (2/37), Chile 8.6% (16/185), Venezuela 8.9% (13/146), and Peru 10.8% (29/268). RT-PCR showed high positive (83.6%) and negative (99.7%) predictive values when compared to the gold standard FISH. In contrast, IHC only showed a high negative predictive value (94.6%). Conclusions: Although there is a clear country and continental variability in terms of ALKr frequency, this difference is not significant and the overall incidence of ALKr in Latin America does not differ from the rest of the world.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121409987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impassion130: Kombinationstherapie von nab-Paclitaxel und Atezolizumab beim metastasierten triple-negativen Mammakarzinom 抗抑郁药:是nab paclitaxel的组合治疗方法，然后是呼吸zolisub的变种

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000496448

A. Wöckel

{"title":"Impassion130: Kombinationstherapie von nab-Paclitaxel und Atezolizumab beim metastasierten triple-negativen Mammakarzinom","authors":"A. Wöckel","doi":"10.1159/000496448","DOIUrl":"https://doi.org/10.1159/000496448","url":null,"abstract":"Patientinnen mit einem nicht kurativ behandelbaren, lokal fortgeschrittenen und metastasierten, triple-negativen (Hormon-Rezeptor-negativen und humaner epidermaler Wachstumsfaktor Rezeptor 2 (HER2-) negativen) Mammakarzinom (TNBC) weisen eine schlechte Prognose auf. Eine Therapie mit Taxan- oder Anthrazyklin-Chemotherapie gilt bei fortgeschrittener Erkrankung als Standardtherapie. Bislang konnte keine zielgerichtete Therapie einen Vorteil beim Gesamtüberleben zeigen. Atezolizumab ist ein humanisierter Antikörper gegen PD-L1, der zu den Checkpoint-Inhibitoren zählt. Bisher ist Atezolizumab in der EU zur Behandlung des fortgeschrittenen Bronchialkarzinoms und des fortgeschrittenen Urothelkarzinoms zugelassen. Nanopartikel-Albumin-gebundenes (nab-) Paclitaxel kann die antineoplastische Aktivität von Atezolizumab optimieren, eine klinische Studie im Sinne eines prospektiv-randomisierten Vergleiches stand bislang aus. In der IMpassion 130-Phase-III-Studie (ClinicalTrials.gov NCT02425891) erhielten 902 Patienten mit unbehandeltem, metastasiertem TNBC randomisiert (Verhältnis 1:1) entweder Atezolizumab plus nab-Paclitaxel oder Placebo plus nab-Paclitaxel. Die beiden primären Endpunkte waren progressionsfreies Überleben sowie Gesamtüberleben. Atezolizumab plus nab-Paclitaxel verlängerte das progressionsfreie Überleben von Patienten mit metastasiertem triple-negativem Brustkrebs in der Intention-to-treat-Population und insbesondere in der PD-L1-positiven Subgruppe.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124961079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wissenschaftlicher Beirat / Impressum / Inhalt 科学委员会/发行/内容

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000499000

引用次数: 0

PharmaNews

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000499002

引用次数: 0

Spektrum Onkologie – wissenswert, kompakt, anregend

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000497794

引用次数: 0

Welche Krebspatienten brauchen psychoonkologische Unterstützung 有哪些癌症病人需要精神肿瘤学支持

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000496284

T. Zimmermann

{"title":"Welche Krebspatienten brauchen psychoonkologische Unterstützung","authors":"T. Zimmermann","doi":"10.1159/000496284","DOIUrl":"https://doi.org/10.1159/000496284","url":null,"abstract":"Objectives: Cancer patients have to cope with anxieties concerning their prognosis, potential recurrence/progression, and treatment-associated sequelae. Stress-related psychosocial factors influence survival and disease-related mortality in cancer patients. Despite improvements in diagnosis and treatment, bladder cancer (BC) remains characterized by high rates of recurrence and progression. We screened pre-therapeutically the stress level of BC patients stratified by gender, disease state, treatment, and other factors by self-administered validated questionnaires to integrate them into psychosocial support as needed. Methods: A cross-sectional analysis of distress and need of psychosocial care was done in 301 patients undergoing treatment for BC by 2 questionnaires (Distress Thermometer [DT] and Hornheider Screening Instrument). Results: Of the 301 patients, 230 patients underwent transurethral resection for a first diagnosis, 63 for recurrent disease, 37 had progressive disease, and 25 had advanced metastatic disease and eventually died of BC. The mean stress level in all patients was 4.6. Twenty-eight percent of the patients expressed a need for psychosocial support. In patients with progressive disease, significantly higher stress scores were seen as well as a higher need of psychosocial care (5.4 and 41%). Conclusions: The median DT-level of 4.6 indicates moderate psychosocial stress in BC patients. From a stress level of 5, the recommendations of a psycho-oncological supervision are pronounced, so that our study showed that early systematic evaluation of psychosocial needs in BC patients is important. © 2018 S. Karger AG, Basel Welche Krebspatienten brauchen psychoonkologische Unterstützung?","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127513774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Zahnextraktion stimuliert die lokale Proliferation eines Multiplen Myeloms bei einer Patientin mit Mandibulabefall 导电干扰会刺激局部多动症的扩散

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000497741

Jean-Daniel Kün-Darbois, Léonie Quenel, Smaïl Badja, Daniel Chappard

{"title":"Zahnextraktion stimuliert die lokale Proliferation eines Multiplen Myeloms bei einer Patientin mit Mandibulabefall","authors":"Jean-Daniel Kün-Darbois, Léonie Quenel, Smaïl Badja, Daniel Chappard","doi":"10.1159/000497741","DOIUrl":"https://doi.org/10.1159/000497741","url":null,"abstract":"Ziele: Das Multiple Myelom (MM) ist durch das Auftreten osteolytischer Läsionen gekennzeichnet. Zur Behandlung des MMs werden meist antiresorptive Arzneimittel (hauptsächlich Bisphosphonate) eingesetzt. Fallbericht: Eine Patientin mit Multiplem Myelom wies osteolytische Mandibulaläsionen auf. 5 Jahre nach Erstdiagnose einer Parodontitis erfolgte eine Extraktion der Zähne 45 und 46. 4 Monate später wurde an der Extraktionsstelle eine Osteonekrose des Kiefers (osteonecrosis of the jaw, ONJ) festgestellt. Die Röntgenaufnahme zeigte eine Vergrößerung der rechtsseitigen osteolytischen Läsionen in der Umgebung der Extraktionsstelle ohne Veränderung der Läsionen auf der linken Seite. 2 Monate später wurde wegen einer schmerzhaften Sequestration des Knochens eine Kürettage durchgeführt. Im Röntgenbild war eine Größenzunahme der rechtsseitigen osteolytischen Läsionen zu erkennen. Ergebnisse: Die histologische Untersuchung ergab ein vaskularisiertes Weichteilplasmozytom in der Umgebung der Kiefernekrose. In der Untersuchung des Knochens zeigten sich gemischte Läsionen mit osteonekrotischen Bereichen und vitalem Knochengewebe, das von aktiven Osteoklasten in der Umgebung des Plasmozytoms resorbiert wurde. Die Oberfläche der osteolytischen Herde hatte sich nur in der Umgebung der Extraktionsstelle erheblich vergrößert. Schlussfolgerungen: Die Zahnextraktion war Auslöser einer Bisphosphonat-assoziierten Kiefernekrose. Sie schien jedoch auch eine deutliche Proliferation der Plasmazellen an der Extraktionsstelle zu induzieren. Unserer Vermutung nach ist diese auf das gesteigerte Remodeling des Knochens infolge des Operationstraumas zurückzuführen.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"424 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116183005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multiples Myelom - es ist vieles im Wandel 多才多艺的Myelom

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000496589

Marcus Hentrich

引用次数: 0

Lebermetastasen beim Mammakarzinom: Resektion ist möglich, aber welche Patientinnen profitieren wirklich 乳房x光切除肝脏转移是可能的但哪些病人能真正受益

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000496593

K. Homayounfar

{"title":"Lebermetastasen beim Mammakarzinom: Resektion ist möglich, aber welche Patientinnen profitieren wirklich","authors":"K. Homayounfar","doi":"10.1159/000496593","DOIUrl":"https://doi.org/10.1159/000496593","url":null,"abstract":"Background: The role of liver resection for metastatic breast carcinoma is still debated. Methods: Fifty-one resected patients were reviewed. All patients received adjuvant chemotherapy after resection of the primary tumor. Clinicopathological characteristics and immunohistochemistry expression of estrogen (ER), progesterone (PR), human epidermal growth factor (HER2), or Ki67 were evaluated. Results: The median number of metastases was 2; single metastases were present in 24 (47%) patients. The median tumor diameter was 4 cm. Major hepatectomies were performed in 31 (61%) patients. Postoperative mortality was null. Postoperative morbidity was 13.7%. The 1-, 5-, and 10-year survival rates were 92, 36, and 16% respectively. Eleven (21.6%) patients survived longer than 5 years and 8.9% are alive without recurrence 10 years after surgery. At the univariate analysis, tumor diameter, lymph node status, PR receptor status, and triple positive receptors (ER+/PR+/Her2+) were significantly related to survival. At the multivariate analysis, tumor diameter, PR receptor, and triple negative status were significantly related to the long-term outcome. Conclusion: Liver resection seems to be a safe and effective treatment for metastases from breast cancer, and encouraging long-term survival can be obtained with acceptable risk in selected patients. Tumors less than 5 cm and positive hormone receptor status are the best prognostic factors.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132540907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sieben Fragen an die Trägerin des José Carreras Best Paper Awards 2018 七个问题的充分的书éCarreras 2018最佳纸业奖

Karger Kompass Onkologie Pub Date : 2019-03-01 DOI: 10.1159/000497739

Sarah Mertlitz

引用次数: 0